Abstract: FR-PO0255
Effect of an Embedded Pharmacist on SGLT2 Inhibitor Use in a CKD Clinic
Session Information
- CKD: Omics, Systemic Stressors, and Targeted Pharmacotherapy
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2201 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Seamons, Todd J., Intermountain Health, Salt Lake City, Utah, United States
- Anderson, Clint, Intermountain Health, Salt Lake City, Utah, United States
- Condie, Chenlee, Intermountain Health, Salt Lake City, Utah, United States
- Butuc, Florin, Intermountain Health, Salt Lake City, Utah, United States
- Bryant, Kevin, Intermountain Health, Salt Lake City, Utah, United States
- Vijayan, Anitha, Intermountain Health, Salt Lake City, Utah, United States
Background
SGLT2 Inhibitors (SGLT2I) are one of the 4 pillars of GDMT in management of patients with CKD and has been demonstrated to slow down progression to ESRD, reduce hospitalizations, and mortality. Despite being widely available, prescription of these drugs remain low, with prevalence in CKD reported to be 15-25% in recent studies. We hypothesized that integration of pharmacist into CKD clinic will increase prescription rates of SGLT2I. We also hypothesized that active medication review and engagement with clinician and patients by pharmacist will drive appropriate prescription of all medications and reduce safety events.
Methods
A pharmacist was assigned to the CKD clinic at Intermountain Health, starting on 1/1/25, one day per week, to work with a single NP as a pilot project, with the primary aim of increasing SGLT2I prescription by 10% over 1 year. The pharmacist was responsible for reviewing NP's clinic schedule one week in advance review charts of any patient not on SGLT2 inhibitors, and make recommendations to the NP on patients who will benefit from SGLT2I - patients with CKD stage 2-4, Type 2 DM, UACR >30mg/g or presence of heart failure. In addition to medication recommendation, pharmacist provided patient education and follow-up.
Results
Over a 9 month period, SGLT2i prescribing increased to 42.5 % from baseline of 33.4% (9.1% increase, Figure 1). During the same period, the prescription rates for other clinicians changed from 32.2% to 31.7%. In addition, during comprehensive medication management (CMM), 370 Medication Therapy Problems (MTPs) were identified, 28% of which were safety related. This resulted in initiation and dose adjustments of other GDMT medications including ACEI, ARB and GLP1 agonists.
Conclusion
Collaboration between a pharmacist and APP in the CKD clinic resulted in signficant increase in prescription of SGLT2 inhibitors over the course of 9 months. In addition, pharmacists was able to identify MTPs, of which a signfiicant percentage were related to medication safety. A large multicenter trial is needed to understand longterm financial impact and safet and quality outcomes of embedding a pharmacist in the CKD clinic.
Acknowledgment
Carrie Dunford, PharmD, Intermountain Health (pharmacy pilot support)